Soliris 300 mg/30 mL Buy Concentrated Infusion Solution – Eculizumab Injection

Soliris 300 mg/30 mL is a life-saving monoclonal antibody infusion containing the active ingredient Eculizumab, developed by Alexion Pharmaceuticals. It is specifically formulated for the treatment of rare, life-threatening blood and immune disorders. As a complement inhibitor, Soliris blocks the activation of complement proteins in the immune system, preventing the destruction of red blood cells and reducing the risk of severe complications in certain diseases.

Key Features:

• Active Ingredient: Eculizumab 300 mg/30 mL (10 mg/mL)
• Form: Concentrated infusion solution (IV administration)
• Administration: Intravenous infusion, requires dilution before use
• Manufacturer: Alexion Pharmaceuticals

Approved Uses:

• Paroxysmal Nocturnal Hemoglobinuria (PNH): Prevents the breakdown of red blood cells, reducing hemolysis and thrombosis risks.
• Atypical Hemolytic Uremic Syndrome (aHUS): Inhibits complement-mediated thrombotic microangiopathy, protecting kidneys and other organs.
• Generalized Myasthenia Gravis (gMG): Effective for adults with anti-AChR antibody-positive gMG.
• Neuromyelitis Optica Spectrum Disorder (NMOSD): Reduces relapses in adults with anti-AQP4 antibody-positive NMOSD.

Benefits:

• Rapid Symptom Relief: Improves quality of life by quickly reducing disease symptoms and progression.
• Life-Saving Treatment: Reduces the risk of severe organ damage and death in patients with complement-mediated disorders.
• Proven Clinical Efficacy: Supported by robust clinical trials showing significant improvement in patient outcomes.

How Does Soliris Work?

Soliris is a complement inhibitor that binds to the protein C5, preventing its cleavage into C5a and C5b. This action blocks the formation of the membrane attack complex (MAC), which is responsible for cell destruction and inflammation in complement-mediated diseases.

Administration and Dosage:

• Administered via intravenous infusion under medical supervision.
• Initial dose: 600 mg every week for 4 weeks, followed by a maintenance dose of 900 mg every 2 weeks.
• Dose adjustments may be required based on patient condition and clinical response.

Storage Instructions:

• Store at 2°C to 8°C (refrigerated).
• Protect from light; do not freeze.

Safety and Warnings:

• Vaccination Required: Patients must receive a meningococcal vaccine at least 2 weeks before starting treatment due to an increased risk of meningococcal infection.
• Common Side Effects: Headache, nausea, fatigue, and upper respiratory tract infections.
• Serious Risks: Potential risk of severe infections; immediate medical attention is required if fever, headache, or neck stiffness occurs.

Why Choose Soliris?

Soliris is a groundbreaking treatment for rare and debilitating complement-mediated diseases, offering unmatched efficacy in controlling symptoms, preventing organ damage, and improving survival rates. It is the gold standard therapy for patients with PNH, aHUS, gMG, and NMOSD.

Buy Soliris 300 mg/30 mL Infusion Solution Online:

We supply authentic Soliris 300 mg/30 mL infusion solutions directly sourced from Alexion Pharmaceuticals. Secure your treatment with trusted, high-quality products and ensure optimal care for rare blood and immune disorders.